SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Job Trends
Top Biopharma M&As in 2019
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
December 30, 2019
 · 
9 min read
 · 
Mark Terry
Business
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
Under the terms of the deal, Scripps will run preclinical R&D, and in some cases, Phase I clinical trials. AbbVie will have an exclusive option to continue development and possible commercialization activities.
December 9, 2019
 · 
4 min read
 · 
Mark Terry
BioCapital
The 12 Days of Christmas, Biopharma Style
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
December 9, 2019
 · 
8 min read
 · 
Mark Terry and Alex Keown
Business
Communicating Diversity and Inclusion: 5 Life Sciences Companies Who Are Nailing It
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
December 2, 2019
 · 
5 min read
 · 
Dana Dunbar, Career Branding Strategist
Business
AbbVie and Harpoon Expand Partnership with $510 Million Licensing Deal
The new deal builds on a discovery agreement signed in October 2017.
November 21, 2019
 · 
2 min read
 · 
Mark Terry
Business
Dragonfly Partners With AbbVie to Take on Autoimmune and Oncology Indications
At the center of the agreement are Dragonfly’s novel NK cell engager-based immunotherapies.
November 20, 2019
 · 
2 min read
 · 
Alex Keown
Drug Development
Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
November 18, 2019
 · 
33 min read
 · 
Tracy Lawton
BioCapital
Clinical Catch-Up: November 11-15
It was a busy week for clinical trial announcements. Here’s a look.
November 15, 2019
 · 
12 min read
 · 
Mark Terry
Genetown
New Pharma Invention Index Picks AstraZeneca as Top Company
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
November 5, 2019
 · 
3 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Business
AbbVie Declares Quarterly Dividend - June 17, 2021
June 17, 2021
 · 
1 min read
Business
Zhongchao Inc. Partners with a Subsidiary of AbbVie Inc. (NYSE: ABBV) for Medical Education Services
June 16, 2021
 · 
3 min read
Drug Development
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
June 12, 2021
 · 
29 min read
Drug Development
New Data Shows AbbVie’s VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
June 11, 2021
 · 
15 min read
Business
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
June 9, 2021
 · 
3 min read
Biotech Beach
Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign
June 8, 2021
 · 
9 min read
Drug Development
CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
June 7, 2021
 · 
27 min read
Drug Development
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
June 4, 2021
 · 
15 min read
BioMidwest
AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 2, 2021
 · 
1 min read
Drug Development
Phase 3 Maintenance Results Show Patients with Crohn’s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year
June 2, 2021
 · 
17 min read
Load More